Zacks Research lowered shares of Daiichi Sankyo (OTCMKTS:DSNKY – Free Report) from a hold rating to a strong sell rating in a research note released on Tuesday morning,Zacks reports.
Separately, Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Daiichi Sankyo presently has an average rating of “Reduce”.
View Our Latest Report on DSNKY
Daiichi Sankyo Trading Down 0.1%
Shares of OTCMKTS DSNKY opened at $17.90 on Tuesday. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $27.50. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $17.79 and a 200-day simple moving average of $17.16. The stock has a market capitalization of $33.35 billion, a PE ratio of 20.81, a PEG ratio of 1.91 and a beta of -0.11.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts forecast that Daiichi Sankyo will post 0.93 earnings per share for the current year.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Recommended Stories
- Five stocks we like better than Daiichi Sankyo
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
